Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
Rhea-AI Summary
IGC Pharma (NYSE American: IGC) said Ascendiant Capital Markets raised its equity research price target to $5.25 on April 8, 2026, citing clinical progress and expected catalysts in 2026.
The company noted its lead program, IGC-AD1, is in a Phase 2 CALMA trial for Alzheimer's-related agitation. IGC clarified analyst reports reflect analysts' views and that IGC is not responsible for analysts' content, accuracy, or timelines.
Positive
- Price target raised to $5.25
- Lead program IGC-AD1 in Phase 2 CALMA trial
- Analyst expects catalysts and more clinical data in 2026
Negative
- Analyst report represents external views and is not company-validated
- No specific new clinical data or timelines disclosed in the announcement
News Market Reaction – IGC
In the Apr 8 session, IGC gained 3.51%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.2% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Media partnership launch | Positive | +0.1% | Announced 12-part national media campaign to expand investor awareness and visibility. |
| Mar 19 | Earnings and clinical update | Positive | -1.3% | Reported fiscal transition results, >70% CALMA enrollment, improved net loss, and patent progress. |
| Mar 18 | AI platform showcase | Positive | -4.7% | Planned ADPD 2026 demo of AHA AI platform with Alzheimer’s Disease Data Initiative. |
| Feb 26 | AI patent filings | Positive | -1.8% | Filed utility patents for AHA architecture after harmonizing 15 Alzheimer’s datasets. |
| Feb 24 | Analyst PT increase | Positive | +4.8% | Ascendiant raised its price target to $5.00 and reiterated research coverage. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements have often seen muted or negative next-day moves, with 3 divergences versus 2 alignments between news tone and price reaction.
Over recent months, IGC has combined clinical and AI development with investor outreach. A 10-KT detailed progress in the Phase 2 CALMA trial and financials, followed by new AI patent filings and conference plans highlighting the AHA platform. The company also pursued strategic media and investor awareness partnerships and obtained updated analyst coverage with a higher price target of $5.00. Despite generally constructive news flow, price reactions have been mixed, making the latest price target increase another step in an ongoing visibility and clinical-progress narrative.
Key Terms
price target financial
equity research report financial
phase 2 medical
clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related agitation today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to
The research report entitled, "Reports Q3. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire